Advances in diagnostics and treatment of visceral leishmaniasis co-infected with HIV

doi:10.12140/j.issn.1000-7423.2020.02.018

Abstract

Abstract:

Visceral leishmaniasis is one of the most serious neglected tropical diseases in the world. The coinfection of Leishmania protozoa with human immunodeficiency virus (HIV) has emerged as a serious threat in endemic areas. Due to the interaction between Leishmania parasite and HIV, the coinfected patients display some special clinical manifestations, different diagnostic signs and treatment effects that cause higher mortality and recurrence rate than patients without HIV coinfection. The article aims to review the advances in the clinical manifestation, diagnostics and treatment of visceral leishmaniasis coinfected with HIV.

Key words: Visceral leishmaniasis, Human immunodeficiency virus, Coinfection, Diagnosis, Treatment

CLC Number:

Xiao-qing HE, Min LIU, Lu ZHOU, Yao-kai CHEN. Advances in diagnostics and treatment of visceral leishmaniasis co-infected with HIV[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2020, 38(2): 245-249.

References 45

[1]	Lindoso JAL, Moreira CHV, Cunha MA , et al. Visceral leishmaniasis and HIV coinfection: current perspectives[J]. HIV AIDS, 2018,10:193-201.
[2]	Zhong YY, Wang JY . Clinical analysis of AIDS coinfected with visceral leishmaniasis[J]. Chin J Prac Med, 2004,4(16):41-42. (in Chinese)
	( 钟玉映, 王俊云 . 艾滋病合并感染黑热病的临床分析[J]. 中华实用医药杂志, 2004,4(16):41-42.)
[3]	Gu Y, Ma CH, Zhou LB . HIV positive patient coinfected with visceral leishmaniasis:a case report[J]. JPMT, 2008(16):2156-2157. (in Chinese)
	( 古月, 马纯华, 周利波 . HIV抗体阳性患者感染黑热病1例[J]. 实用医技杂志, 2008(16):2156-2157.)
[4]	Zhang GX, Cao BL , Xing JY. HIV coinfected with visceral leishmaniasis:a case report [J]. Chin J Derm Venereol, 2010, 24(11): 1072, 1074. (in Chinese)
	( 张更新, 曹碧兰, 幸建英 . 艾滋病合并感染黑热病1例[J]. 中国皮肤性病学杂志, 2010, 24(11): 1072, 1074.)
[5]	Xia HJ, Yi YL, Liao YQ . Analysis of misdiagnosis about three cases with leishmaniasis and HIV co-infection[J]. Chin J Derm Venereol, 2011,25(7):567-568. (in Chinese)
	夏洪娇, 易运林, 廖永强 . 黑热病合并HIV感染3例误诊分析[J]. 中国皮肤性病学杂志, 2011,25(7):567-568.
[6]	Baoyixiamu·ABBKL, Pan KJ Maimaitiaili·XBL , et al. AIDS with kala-azar:a case report[J]. Chin J Viral Dis, 2012,2(6):75-76. (in Chinese)
	( 包依夏姆·阿巴拜克力, 潘珂君买买提艾力·吾布力, , 等. 艾滋病合并黑热病1例分析[J]. 中国病毒病杂志, 2012,2(6):75-76.)
[7]	Song SH, Gui XE . Follow-up of a patient with Leishmania and human immunodeficiency virus co-infection who received prolonged sodium stibogluconate treatments[J]. Chin J Parasitol Parasit Dis, 2018,36(2):148-152. (in Chinese)
	( 宋世会, 桂希恩 . 葡萄糖酸锑钠长疗程治疗1例利什曼原虫与人类免疫缺陷病毒合并感染患者的追踪观察[J]. 中国寄生虫学与寄生虫病杂志, 2018,36(2):148-152.)
[8]	Guan LR, Gao CH . Leishmaniasis and its control[J]. Chin J Parasitol Parasit Dis, 2018,36(4):418-424, 428. (in Chinese)
	( 管立人, 高春花 . 利什曼病及其防治[J]. 中国寄生虫学与寄生虫病杂志, 2018,36(4):418-424, 428.)
[9]	Lindoso JA ,Cota GF, da Cruz AM, et al. Visceral leishmaniasis and HIV coinfection in Latin America[J]. PLoS Negl Trop Dis, 2014,8(9):e3136.
[10]	Lima IP, Müller MC ,HolandaTA, et al. Human immunodeficiency virus/Leishmania infantum in the frst foci of urban American visceral leishmaniasis: clinical presentation from 1994 to 2010[J]. Rev Soc Bras Med Trop, 2013,46(2):156-160.
[11]	Wang J, Guan LR . Leishmaniasis and HIV coinfection:a problem of leishmaniasis[J]. Foreign Med Sci Parasit Dis, 2004,31(4):169-172. (in Chinese)
	( 王捷, 管立人 . 利什曼原虫与艾滋病病毒的合并感染: 利什曼病防治上值得重视的一个问题[J]. 国外医学(寄生虫病分册), 2004,31(4):169-172.)
[12]	Cota GF, de Sousa MR, de Mendonça AL , et al. Leishmania-HIV coinfection: clinical presentation and outcomes in an urban area in Brazil[J]. LoS Negl Trop Dis, 2014,8(4):e2816.
[13]	WHO. Control of the leishmaniases[R]. Geneva: World Health Organization, 2010.
[14]	Srivastava P, Dayama A, Mehrotra S , et al. Diagnosis of visceral leishmaniasis[J]. Trans R Soc Trop Med Hyg, 2011,105(1):1-6.
[15]	Burza S, Croft SL, Boelaert M . Leishmaniasis--author’s reply[J]. Lancet, 2019,393(10174):872-873.
[16]	Nuzum E, White F, Thakur C , et al. Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood[J]. J Infect Dis, 1995,171(3):751-754.
[17]	de Ruiter CM, van der Veer C, Leeflang MM , et al . Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy[J]. J Clin Microbiol, 2014,52(9):3147-3155.
[18]	Mary C, Faraut F, Lascombe L , et al. Quantifcation of Leishmania infantum DNA by a real-time PCR assay with high sensitivity[J]. J Clin Microbiol, 2004,42:5249-5255.
[19]	Bourgeois N, Bastien P, Reynes J , et al. ‘Active chronic visceral leishmaniasis’ in HIV-1-infected patients demonstrated by biological and clinical long-term followup of 10 patients[J]. HIV Med, 2010,11(10):670-673.
[20]	Cota GF, de Sousa MR, Demarqui FN , et al . The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis[J]. PLoS Negl Trop Dis, 2012,6(5):e1665.
[21]	Cunningham J, Hasker E, Das P , et al. A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis[J]. Clin Infect Dis, 2012,55(10):1312-1319.
[22]	Cota GF, de Sousa MR, Nogueira BM , et al . Comparison of parasitological, serological, and molecular tests for visceral leishmaniasis in HIV-infected patients: a cross-sectional delayed-type study[J]. Am J Trop Med Hyg, 2013,89(3):570-577.
[23]	Riera C, Fisa R, Lopez P , et al. Evaluation of a latex agglutination test (KAtex) for detection of Leishmania antigen in urine of patients with HIV-Leishmania coinfection: value in diagnosis and post-treatment follow-up[J]. Eur J Clin Microbiol Infect Dis, 2004,23(12):899-904.
	Frézard F, Demicheli C, Ribeiro RR . Pentavalent antimonials: new perspectives for old drugs[J]. Molecules, 2009,14(7):2317-2336.
[24]	Croft SL, Yardley V . Chemotherapy of leishmaniasis[J]. Curr Pharm Des, 2002,8(4):319-342.
[26]	Pintado V, López-Vélez R . HIV-associated visceral leishmaniasis[J]. Clin Microbiol Infect, 2001,7(6):291-300.
[27]	Cota GF, de Sousa MR, Fereguetti TO , et al . Effcacy of antiLeishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison[J]. PLoS Negl Trop Dis, 2013,7(5):e2195.
[28]	Ritmeijer K, Dejenie A, Assefa Y , et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection[J]. Clin Infect Dis, 2006,43(3):357-364.
[29]	World Heath Organization . Control of the leishmaniases[M]. Geneva: WHO, 2010.
[30]	Sinha PK, van Griensven J, Pandey K , et al . Liposomal amphotericin B for visceral leishmaniasis in human immunodefciency virus-coinfected patients: 2-year treatment outcomes in Bihar, India[J]. Clin Infect Dis, 2011,53(7):e91-e98.
[31]	Balasegaram M, Ritmeijer K, Lima MA , et al. Liposomal amphotericin B as a treatment for human leishmaniasis[J]. Expert Opin Emerg Drugs, 2012,17(4):493-510.
[32]	Sundar S, Singh A . Chemotherapeutics of visceral leishmaniasis: present and future developments[J]. Parasitology, 2018,145(4):481-489.
[33]	Dorlo TP, Huitema AD, Beijnen JH , et al. Optimal dosing of miltefosine in children and adults with visceral leishmaniasis[J]. Antimicrob Agents Chemother, 2012,56(7):3864-3872.
[34]	Sindermann H, Engel KR, Fischer C , et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection[J]. Clin Infect Dis, 2004,39(10):1520-1523.
[35]	Garg R, Tremblay MJ . Miltefosine represses HIV-1 replication in human dendritic cell/T-cell cocultures partially by inducing secretion of type-I interferon[J]. Virology, 2012,432(2):271-276.
[36]	Hendrickx S, Boulet G, Mondelaers A , et al. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum[J]. Parasitol Res, 2014,113(5):1875-1881.
[37]	Singh N, Kumar M, Singh RK . Leishmaniasis: current status of available drugs and new potential drug targets[J]. Asian Pac J Trop Med, 2012,5(6):485-497.
[38]	Kuhlencord A, Maniera T, Eibl H , et al. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice[J]. Antimicrob Agents Chemother, 1992,36(8):1630-1634.
[39]	Mahajan R, Das P, Isaakidis P , et al. Combination treatment for visceral leishmaniasis patients coinfected with human immunodefciency virus in India[J]. Clin Infect Dis, 2015,61(8):1255-1262.
[40]	López-Vélez R, Videla S, Márquez M , et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients[J]. J Antimicrob Chemother, 2004,53(3):540-543.
[41]	Molina I, Falcó V, Crespo M , et al. Effcacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients[J]. J Antimicrob Chemother, 2007,60(4):837-842.
[42]	Diro E, Ritmeijer K, Boelaert M , et al. Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study[J]. PLoS Negl Trop Dis, 2015,9(10):e0004087.
[43]	Marques N, Sá R, Coelho F , et al. Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients[J]. Scand J Infect Dis, 2008,40(6/7):523-526.
[44]	Burza S, Mahajan R, Sinha PK , et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)[J]. PLoS Negl Trop Dis, 2014,8(8):e3053.
[45]	van Griensven J, Diro E, Lopez-Velez R , et al. HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals[J]. Lancet Infect Dis, 2013,13(3):251-259.